Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $215 | $991 | $1,065 | $3,588 |
| - Cash | $34 | $28 | $43 | $60 |
| + Debt | $40 | $43 | $47 | $46 |
| Enterprise Value | $221 | $1,006 | $1,069 | $3,575 |
| Revenue | $67 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $67 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$186 | -$248 | -$226 | -$207 |
| % Margin | -276.1% | – | – | – |
| Net Income | -$166 | -$292 | -$237 | -$159 |
| % Margin | -246% | – | – | – |
| EPS Diluted | -2.33 | -4.47 | -4.48 | -3.72 |
| % Growth | 47.9% | 0.2% | -20.4% | – |
| Operating Cash Flow | -$171 | -$208 | -$164 | -$154 |
| Capital Expenditures | -$0 | -$1 | -$3 | -$6 |
| Free Cash Flow | -$171 | -$208 | -$166 | -$160 |